 |
Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997
Rigel Pharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference
South San Francisco, CA - October 16, 2003
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, Senior Vice President of Business Development and Commercial Operations, is scheduled to present at the 5th Annual Rodman & Renshaw Techvest Healthcare Conference at 9:40 a.m. Eastern Time, October 21, 2003 at Boston Marriott Long Wharf Hotel.
Event: |
Rodman and Renshaw Techvest Healthcare Conference |
Location: |
Boston Marriott Long Wharf Hotel
Boston, MA |
Date: |
October 21, 2003 |
Speaker: |
Raul R. Rodriguez, Senior Vice President of Business Development and Commercial Operations
Tuesday, October 21, 2003, 9:40 a.m. Eastern Time |
Highlights: |
Mr. Rodriguez will discuss Rigel’s current and upcoming clinical candidates in allergic rhinitis, hepatitis C, rheumatoid arthritis and asthma. He will discuss the company’s business model to develop a portfolio of drug candidates, to demonstrate efficacy in humans for select compounds and then to seek pharmaceutical partners for further clinical development and marketing. |
For those who are unable to attend the conference, there will be a live audio webcast of Rodriguez’s presentation which can be accessed by going to:
http://www.wallstreetwebcasting.com/webcast/rrshq/rigl/
A replay will be available at the same site for 90 days.
About Rigel (www.rigel.com)
Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs. Rigel has identified three lead product development programs: mast cell inhibition to treat immunologic diseases such as asthma/allergy and autoimmune disorders, antiviral agents to treat hepatitis C, and ligases, a new class of cancer drug targets. Rigel has begun clinical testing of its first product candidate, R112, for allergic rhinitis, and plans to begin clinical trials of three additional drug candidates for the treatment of hepatitis C, rheumatoid arthritis and asthma through the end of 2004.
Rigel Contact: Raul Rodriguez (1-650-624-1302)
|
|
rigel in the news
